Jose F Camargo

List of Publications by Year
in descending order

73 papers	1,700 citations	361413 20 h-index	302126 39 g-index
73 all docs	73 docs citations	73 times ranked	2848 citing authors

#	Article	IF	Citations
1	Invasive Aspergillosis in solidâ€organ transplant recipients: Guidelines from the American Society of Transplantation Infectious Diseases Community of Practice. Clinical Transplantation, 2019, 33, e13544.	1.6	160
2	COVID-19 in solid organ transplant recipients: A systematic review and meta-analysis of current literature. Transplantation Reviews, 2021, 35, 100588.	2.9	159
3	CCL3L1 and CCR5 influence cell-mediated immunity and affect HIV-AIDS pathogenesis via viral entry-independent mechanisms. Nature Immunology, 2007, 8, 1324-1336.	14.5	152
4	CCL3L1-CCR5 genotype influences durability of immune recovery during antiretroviral therapy of HIV-1â€“infected individuals. Nature Medicine, 2008, 14, 413-420.	30.7	118
5	Emerging concepts in cytomegalovirus infection following hematopoietic stem cell transplantation. Hematology/ Oncology and Stem Cell Therapy, 2017, 10, 233-238.	0.9	78
6	Immune Correlates of Protection in Human Invasive Aspergillosis. Clinical Infectious Diseases, 2014, 59, 569-577.	5.8	73
7	CCR5 Expression Levels Influence NFAT Translocation, IL-2 Production, and Subsequent Signaling Events during T Lymphocyte Activation. Journal of Immunology, 2009, 182, 171-182.	0.8	71
8	Influence of the Timing of Antiretroviral Therapy on the Potential for Normalization of Immune Status in Human Immunodeficiency Virus 1â€“Infected Individuals. JAMA Internal Medicine, 2015, 175, 88.	5.1	69
9	Successful Treatment of Carbapenemase-Producing Pandrug-Resistant Klebsiella pneumoniae Bacteremia. Antimicrobial Agents and Chemotherapy, 2015, 59, 5903-5908.	3.2	54
10	Clinical â€œrealâ€worldâ€•experience with letermovir for prevention of cytomegalovirus infection in allogeneic hematopoietic cell transplant recipients. Clinical Transplantation, 2020, 34, e13866.	1.6	48
11	Responsiveness of T Cells to Interleukinâ€7 Is Associated with Higher CD4+T Cell Counts in HIVâ€1â€“Positive Individuals with Highly Active Antiretroviral Therapyâ€“Induced Viral Load Suppression. Journal of Infectious Diseases, 2009, 199, 1872-1882.	4.0	46
12	Impact of Cytomegalovirus Viral Load on Probability of Spontaneous Clearance and Response to Preemptive Therapy in Allogeneic Stem Cell Transplantation Recipients. Biology of Blood and Marrow Transplantation, 2018, 24, 806-814.	2.0	46
13	Deep functional immunophenotyping predicts risk of cytomegalovirus reactivation after hematopoietic cell transplantation. Blood, 2019, 133, 867-877.	1.4	42
14	Next-generation sequencing of microbial cell-free DNA for rapid noninvasive diagnosis of infectious diseases in immunocompromised hosts. F1000Research, 2019, 8, 1194.	1.6	37
15	Twelve-Week Rifapentine Plus Isoniazid Versus 9-Month Isoniazid for the Treatment of Latent Tuberculosis in Renal Transplant Candidates. Transplantation, 2017, 101, 1468-1472.	1.0	33
16	Next-generation sequencing of microbial cell-free DNA for rapid noninvasive diagnosis of infectious diseases in immunocompromised hosts. F1000Research, 0, 8, 1194.	1.6	33
17	Solid organ transplant antibiograms: an opportunity for antimicrobial stewardship. Diagnostic Microbiology and Infectious Disease, 2016, 86, 460-463.	1.8	27
18	Clinical presentation and outcomes of COVIDâ€19 following hematopoietic cell transplantation and cellular therapy. Transplant Infectious Disease, 2021, 23, e13625.	1.7	24

#	Article	IF	Citations
19	Impact of antiretroviral therapy on clinical outcomes in HIV+ kidney transplant recipients: Review of 58 cases. F1000Research, 2016, 5, 2893.	1.6	24
20	CCL3L1-CCR5 Genotype Improves the Assessment of AIDS Risk in HIV-1-Infected Individuals. PLoS ONE, 2008, 3, e3165.	2.5	23
21	The use of brincidofovir for the treatment of mixed dsDNA viral infection. Journal of Clinical Virology, 2016, 83, 1-4.	3.1	23
22	A cluster of donorâ€derived <scp>C</scp>ryptococcus neoformans infection affecting lung, liver, and kidney transplant recipients: Case report and review of literature. Transplant Infectious Disease, 2018, 20, e12836.	1.7	22
23	Linezolid- and Vancomycin-resistant Enterococcus faecium in Solid Organ Transplant Recipients: Infection Control and Antimicrobial Stewardship Using Whole Genome Sequencing. Clinical Infectious Diseases, 2019, 69, 259-265.	5.8	22
24	Impaired T Cell Responsiveness to Interleukin-6 in Hematological Patients with Invasive Aspergillosis. PLoS ONE, 2015, 10, e0123171.	2.5	21
25	Influence of immune activation on the risk of allograft rejection in human immunodeficiency virus-infected kidney transplant recipients. Transplant Immunology, 2016, 38, 40-43.	1.2	21
26	Implementation of a Strongyloides screening strategy in solid organ transplant donors and recipients. Clinical Transplantation, 2019, 33, e13497.	1.6	21
27	Production of Specific mRNA Transcripts, Usage of an Alternate Promoter, and Octamer-Binding Transcription Factors Influence the Surface Expression Levels of the HIV Coreceptor CCR5 on Primary T Cells. Journal of Immunology, 2007, 178, 5668-5681.	0.8	20
28	Progressive multifocal leukoencephalopathy after CAR T therapy. International Journal of Hematology, 2020, 112, 118-121.	1.6	18
29	Application of â€œPrecision Medicineâ€•Through the Molecular Characterization of Extensively Drug-Resistant Klebsiella pneumoniae in a Multivisceral Transplant Patient. Clinical Infectious Diseases, 2017, 65, 701-702.	5.8	15
30	â€œDouble carbapenemâ€•and oral fosfomycin for the treatment of complicated urinary tract infections caused by bla_{NDM}â€harboring Enterobacteriaceae in kidney transplantation. Transplant Infectious Disease, 2018, 20, e12795.	1.7	15
31	Reduced immunogenicity of the adjuvanted recombinant zoster vaccine after hematopoietic cell transplant: a pilot study. Blood Advances, 2020, 4, 4618-4622.	5.2	15
32	Kidney transplantation during coronavirus 2019 pandemic at a large hospital in Miami. Transplant Infectious Disease, 2020, 22, e13416.	1.7	14
33	Donorâ€derived infections in solid organ transplant recipients: Challenging the 30â€day paradigm. Transplant Infectious Disease, 2017, 19, e12665.	1.7	13
34	Clinical outcomes of intestinal transplant recipients colonized with multidrug-resistant organisms: a retrospective study. Transplant International, 2017, 30, 924-931.	1.6	13
35	Clinical outcomes in HIV+/HCV+ coinfected kidney transplant recipients in the preâ€•and postâ€directâ€acting antiviral therapy eras: 10â€Year single center experience. Clinical Transplantation, 2019, 33, e13532.	1.6	12
36	Intravenous Fosfomycin Treatment for Carbapenem-Resistant Klebsiella pneumoniae in the United States. Annals of Pharmacotherapy, 2015, 49, 1177-1178.	1.9	9

#	Article	IF	Citations
37	Clostridium difficile infection in intestinal transplant recipients. Transplant International, 2018, 31, 116-117.	1.6	9
38	Lack of correlation between the SARSâ€CoVâ€2 cycle threshold (C_t) value and clinical outcomes in patients with COVIDâ€19. Journal of Medical Virology, 2021, 93, 6059-6062.	5.0	8
39	Successful Treatment of Primary Cutaneous Mucormycosis Complicating Anti-TNF Therapy with a Combination of Surgical Debridement and Oral Posaconazole. Mycopathologia, 2015, 180, 187-192.	3.1	7
40	Severe hypertension after initiation of rifapentine/isoniazid for latent tuberculosis in renal transplant candidates. Transplant International, 2017, 30, 108-109.	1.6	7
41	Challenges in Antimicrobial Stewardship: Rapid Diagnostics and Optimization of Therapy Among Immunocompromised Patients. Open Forum Infectious Diseases, 2019, 6, ofz239.	0.9	6
42	Use of maintenance therapy and incidence of recurrent Cytomegalovirus DNAemia among allogeneic hematopoietic cell transplant recipients. Transplant Infectious Disease, 2019, 21, e13054.	1.7	5
43	Bloodstream infection caused by enteric organisms during the first 6Âmonths after intestinal transplant. Transplant Infectious Disease, 2019, 21, e13064.	1.7	5
44	Antimicrobial resistance and recurrent bacterial urinary tract infections in hospitalized patients following kidney transplantation: A singleâ€center experience. Transplant Infectious Disease, 2020, 22, e13337.	1.7	5
45	Successful Treatment of Invasive Fungal Infection Due to Highly Resistant Aspergillus calidoustus in an Allogeneic Hematopoietic Cell Transplant Recipient. Mycopathologia, 2020, 185, 399-403.	3.1	5
46	nLower incidence of Cytomegalovirus reactivation following post-transplant cyclophosphamide HLA mismatched unrelated donor transplantation. Transplantation and Cellular Therapy, 2021, 27, 1017.e1-1017.e1.	1.2	5
47	Early antibiotic use is associated with CMV risk and outcomes following allogeneic hematopoietic cell transplantation. Blood Advances, 2020, 4, 6364-6367.	5.2	5
48	Failure of atovaquone prophylaxis for prevention of toxoplasmosis in hematopoietic cell transplant recipients. Transplant Infectious Disease, 2020, 22, e13198.	1.7	4
49	Next-generation sequencing of microbial cell-free DNA for rapid noninvasive diagnosis of infectious diseases in immunocompromised hosts. F1000Research, 0, 8, 1194.	1.6	4
50	Successful Treatment of Disseminated Disease Due to Highly Resistant Aspergillus calidoustus with a Novel Antifungal Therapy. Antimicrobial Agents and Chemotherapy, 2022, 66, aac0220621.	3.2	4
51	The role of preemptive antimicrobial therapy in kidney recipients of urineâ€only positive donor cultures. Transplant Infectious Disease, 2019, 21, e13150.	1.7	3
52	Pretransplant Levels of C-Reactive Protein,ÂSoluble TNF Receptor-1, andÂCD38+HLADR+ CD8 T Cells Predict Risk of Allograft Rejection in HIV+ Kidney Transplant Recipients. Kidney International Reports, 2019, 4, 1705-1716.	0.8	3
53	Treatment of latent tuberculosis infection with shortâ€course regimens in potential living kidney donors. Transplant Infectious Disease, 2020, 22, e13244.	1.7	3
54	Addition Of Oral Fosfomycin To Antimicrobial Salvage Therapy For Persistent Vancomycin-Resistant Enterococcal Bacteremia. Clinical Infectious Diseases, 2021, , .	5.8	3

#	Article	IF	Citations
55	Impact of Viral Load on Eradication of Cytomegalovirus (CMV) Viremia Amongst High-risk Allogeneic Stem Cell Transplant (SCT) Recipients. Open Forum Infectious Diseases, 2016, 3, .	0.9	2
56	Decrease in eosinophilia as a marker of response to therapy in solid organ transplant candidates with Strongyloides infection: A singleâ€center experience. Transplant Infectious Disease, 2018, 20, e12954.	1.7	2
57	Saddle Nose Deformity in an Immunosuppressed Patient. Clinical Infectious Diseases, 2019, 68, 705-709.	5.8	2
58	Aseptic Meningitis after Recovery from SARS-CoV-2 in an Allogeneic Stem Cell Transplant Recipient. Clinical Medicine Insights: Case Reports, 2021, 14, 117954762110098.	0.7	2
59	Viral kinetics and outcomes of adenovirus viremia following allogeneic hematopoietic cell transplantation. Clinical Transplantation, 2021, 35, e14481.	1.6	2
60	Next-generation sequencing of microbial cell-free DNA for rapid noninvasive diagnosis of infectious diseases in immunocompromised hosts. F1000Research, 0, 8, 1194.	1.6	2
61	Application of "Precision Medicine" Through the Molecular Characterization of Extensively Drug Resistant (XDR) Klebsiella pneumoniae in a Multivisceral Transplant Candidate. Open Forum Infectious Diseases, 2016, 3, .	0.9	1
62	Functional Signatures Revealed by Deep Phenotyping of CMV-Specific CD8+ T Cells Predict Risk of Early CMV Reactivation after Allogeneic Hematopoietic Cell Transplantation. Biology of Blood and Marrow Transplantation, 2018, 24, S99.	2.0	1
63	Invasive Rhinosinusitis Caused by Lasiodiplodia theobromae in an Allogeneic Hematopoietic Cell Transplant Recipient Case Report and Review of Literature. Mycopathologia, 2018, 183, 841-845.	3.1	1
64	Efficacy and tolerability of fosfomycin in prevention of recurrent urinary tract infections among kidney transplant recipients. Transplant Infectious Disease, 2019, 21, e13042.	1.7	1
65	Functional Signatures Revealed By Deep Phenotyping of CMV-Specific CD8+ T Cells Predict Risk of Early CMV Reactivation after Allogeneic Hematopoietic Cell Transplantation. Blood, 2017, 130, 746-746.	1.4	1
66	Cytomegalovirus in Hematopoietic Stem Cell Transplant Recipients: Prevention, Diagnosis, and Treatment. , 2020, , 1-44.		1
67	2395. Mechanism-Based-Susceptibility Testing (MBST) Using Disc Diffusion Assays (DDA) to Guide Treatment of Multidrug- and Extensively Drug-Resistant Pseudomonas aeruginosa (MDR-XDR-Pa) in a Cystic Fibrosis (CF) Lung Transplant Recipient; Are We Ready for Combination Therapy vs. MDR-XDR-Pa?. Open Forum Infectious Diseases, 2018, 5, S714-S714.	0.9	0
68	Solving the mystery: Hyalinized cyst wall containing organismâ€like structures in a lung transplant donor. Transplant Infectious Disease, 2018, 20, e12940.	1.7	0
69	Solid organ transplantation from Zika IgM positive donors: Not always a true positive. Clinical Transplantation, 2019, 33, e13492.	1.6	0
70	Screening of human Tâ€lymphotropic virus among solid organ transplant candidates at a large transplant center. Clinical Transplantation, 2020, 34, e13825.	1.6	0
71	Cytomegalovirus in Hematopoietic Stem Cell Transplant Recipients: Prevention, Diagnosis, and Treatment. , 2021, , 573-616.		0
72	1103. Respiratory Virus Infections In Solid Organ Transplant Recipients: A Single Center Experience. Open Forum Infectious Diseases, 2020, 7, S581-S582.	0.9	0

#	Article	IF	Citations
73	1347. Comparison Between SARS-Cov-2, non-SARS-Cov-2 Coronavirus, Influenza and RSV Infections Among Solid Organ Transplant Recipients. Open Forum Infectious Diseases, 2021, 8, S760-S761.	0.9	0